,company,datePublished,author,headline,description,articleBody,tags,url
0,OCP,2017-12-13T15:32:20+05:30,"{'@type': 'Person', 'url': 'https://www.moneycontrol.com/author/pti-6883/', 'name': 'PTI'}",Orchid Pharma gets USFDA nod for schizophrenia drug,"In a filing to BSE, the company said it &amp;quot;has received ANDA (abbreviated new drug application) approval from USFDA (United States Food and Drug Administration) for Aripiprazole Orally-Disintegrating tablets USP, 10 mg and 15 mg.&amp;quot;","Orchid Pharma today said it has received approval from the US health regulator for Aripiprazole Orally-Disintegrating tablets, used in treatment of schizophrenia and bipolar disorder.  In a filing to BSE, the company said it &amp;quot;has received ANDA (abbreviated new drug application) approval from USFDA (United States Food and Drug Administration) for Aripiprazole Orally-Disintegrating tablets USP, 10 mg and 15 mg.&amp;quot;  The tablets are atypical antipsychotic, indicated in the treatment of symptoms related to psychotic conditions such as schizophrenia and bipolar disorder (manic depression), it added.  Shares of the company were trading 4.87 per cent up at Rs 18.30 on BSE.","Business, Companies, Orchid Pharma, USFDA",https://www.moneycontrol.com//news/business/orchid-pharma-gets-usfda-nod-for-schizophrenia-drug_10211121.html
1,OCP,2017-09-21T15:33:10+05:30,"{'@type': 'Person', 'name': 'Faizan Javed'}",Orchid Pharma gets EIR from USFDA for its Alathur facility,"The company has received EIR from the United States Food and Drug Administration (USFDA) based on the successful inspection of the active pharmaceutical ingredients (API) manufacturing facility at Alathur, Orchid Pharma said in a filing to BSE.","Orchid Pharma today said it has received establishment inspection report (EIR) from the US health regulator for its Alathur facility in Tamil Nadu.  The company has received EIR from the United States Food and Drug Administration (USFDA) based on the successful inspection of the active pharmaceutical ingredients (API) manufacturing facility at Alathur, Orchid Pharma said in a filing to BSE.  The facility was inspected by the USFDA on May 2017, it added. Orchid Pharma stock shot up nearly 20 per cent to Rs 21.45 per scrip in the afternoon trade on BSE.","BSE, Business, Companies, Orchid Pharma, pharma, USFDA",https://www.moneycontrol.com//news/business/orchid-pharma-gets-eirusfda-for-its-alathur-facility_9725341.html
2,OCP,2017-09-18T12:18:12+05:30,"{'@type': 'Person', 'name': 'BSE Notices'}",Orchid Pharma: Outcome of AGM,"VOTING RESULTS OF THE 24TH ANNUAL GENERAL MEETING IN THE REVISED FORMAT AS SPECIFIED IN THE SEBI CIRCULAR CIR/CFD/CMD/8/2015 DATED NOVEMBER 04,2015","VOTING RESULTS OF THE 24TH ANNUAL GENERAL MEETING IN THE REVISED FORMAT AS SPECIFIED IN THE SEBI CIRCULAR CIR/CFD/CMD/8/2015 DATED NOVEMBER 04,2015Source : BSE",Announcements,https://www.moneycontrol.com//news/announcements/orchid-pharma-outcomeagm_9700441.html
3,OCP,2017-08-22T20:53:59+05:30,"{'@type': 'Person', 'name': 'BSE Notices'}","Orchid Pharma's AGM held on September 13, 2017","We kindly want to inform you that the Annual General Meeting to be held on September 13, 2017.","Intimation of the Notice of AGM to be held on September 13, 2017.Source : BSE",Announcements,https://www.moneycontrol.com//news/announcements/orchid-pharma39s-agm-heldseptember-13-2017_9525221.html
4,OCP,2017-07-26T08:41:22+05:30,"{'@type': 'Person', 'name': 'Faizan Javed'}","Orchid Pharma settles case with Sebi, pays Rs 5.25 lakh","In an order dated July 24, the Securities and Exchange Board of India (Sebi) settled the &amp;quot;possible proceedings&amp;quot; against Orchid Pharma related to alleged non-compliances by the firm of Sebi's ICDR (Issue of Capital and Disclosure Requirements) Regulations.","Orchid Pharma has settled a case related to alleged violation of disclosure norms with markets regulator Sebi after payment of Rs 5.25 lakh as settlement charges.  In an order dated July 24, the Securities and Exchange Board of India (Sebi) settled the &amp;quot;possible proceedings&amp;quot; against Orchid Pharma related to alleged non-compliances by the firm of Sebi's ICDR (Issue of Capital and Disclosure Requirements) Regulations.  Orchid Pharma had filed an application with the regulator under settlement mechanism, that provides for settlement of cases without admitting or denying the charges.  The settlement terms proposed by the firm were considered by Sebi's High Powered Advisory Committee (HPAC), which recommended the case for settlement on payment of Rs 5.25 lakh by the company. The recommendation of HPAC was also accepted by the panel of whole-time members of the regulator.  Last month, the company paid the settlement amount of Rs 5.25 lakh and accordingly Sebi disposed of the possible proceedings.  However, Sebi said if any representation made by the firm in the settlement proceedings is subsequently discovered to be untrue, enforcement actions including commencing of proceedings can be initiated against it.","Business, ICDR, Orchid Pharma, SEBI",https://www.moneycontrol.com//news/business/orchid-pharma-settles-casesebi-pays-rs-525-lakh_9331021.html
5,OCP,2017-04-18T13:13:57+05:30,"{'@type': 'Person', 'name': 'webtech_news18'}",Orchid Pharma receives establishment inspection report from USFDA,"Orchid Pharma has received the establishment inspection report (EIR) from USFDA based on the successful inspection of the formulation manufacturing facility located at Tamil Nadu, India.",Establishment Inspection Report from USFDASource : BSE Read all announcements in Orchid Pharma,Announcements,https://www.moneycontrol.com//news/announcements/orchid-pharma-receives-establishment-inspection-reportusfda_8791501.html
6,OCP,2017-04-18T13:13:56+05:30,"{'@type': 'Person', 'name': 'BSE Notices'}",Orchid Pharma receives establishment inspection report from USFDA,"Orchid Pharma has received the establishment inspection report (EIR) from USFDA based on the successful inspection of the formulation manufacturing facility located at Tamil Nadu, India.",Establishment Inspection Report from USFDASource : BSE,Announcements,https://www.moneycontrol.com//news/announcements/orchid-pharma-receives-establishment-inspection-reportusfda_8791521.html
7,OCP,2017-04-07T15:46:16+05:30,"{'@type': 'Person', 'name': 'Rakesh Patil'}","Sell Orchid Pharma on rally, says Vijay Chopra",Vijay Chopra of enochventures.com advises selling Orchid Pharma.,"Vijay Chopra of enochventures.com told CNBC-TV18, &amp;quot;Fundamentally speaking I looked at the balance sheet of Orchid Pharma and it is stressed. I would say that there are better opportunities in the pharma space if somebody wants to buy into those stocks. Wockhardt looks much better structurally and according to the balance sheet also one can get into the stock at this point of time.&amp;quot;  &amp;quot;Even Sun Pharmaceutical looks good but stock like Orchid Pharma I would suggest that one should get out on rallies as soon as possible because its balance sheets are stressed and I would say that it is not a good idea to stay in that stock, so better get out and get into some better story,&amp;quot; he added.","Orchid Pharma, Stocks Views, Sun Pharmaceutical, Vijay Chopra, Wockhardt",https://www.moneycontrol.com//news/stocks-views/sell-orchid-pharmarally-says-vijay-chopra_8752601.html
8,OCP,2017-04-07T15:36:29+05:30,"{'@type': 'Person', 'name': 'Rakesh Patil'}","Exit Orchid Pharma, says Prakash Gaba","According to Prakash Gaba of prakashgaba.com, one may exit Orchid Pharma.","Prakash Gaba of prakashgaba.com told CNBC-TV18, &amp;quot;So far Orchid Pharma has formed a base here. The structure is weak, so it has just formed a base and has given a breakout at Rs 29. Even if it does go up it is likely to find resistances, stiff resistance closer to Rs 36, one should exit there.&amp;quot;  The share touched its 52-week high Rs 45.90 and 52-week low Rs 23.70 on 22 April, 2016 and 22 November, 2016, respectively.","Orchid Pharma, Prakash Gaba of prakashgaba.com, Stocks Views",https://www.moneycontrol.com//news/stocks-views/exit-orchid-pharma-says-prakash-gaba_8752561.html
9,OCP,2017-02-07T16:28:03+05:30,"{'@type': 'Person', 'name': 'Faizan Javed'}",Orchid Pharma Q3 net loss narrows to Rs 60.97 cr,"The company had posted a net loss of Rs 94.02 crore in the year-ago period, Orchid Pharma said in a BSE filing.","Drug firm Orchid Pharma's standalone net loss narrowed to Rs 60.97 crore during the quarter ended December 31, 2016. The company had posted a net loss of Rs 94.02 crore in the year-ago period, Orchid Pharma said in a BSE filing. Its standalone total income from operations also declined to Rs 179.98 crore during the quarter under review from Rs 205.87 crore a year ago. Shares of Orchid Pharma today closed 2.47 percent down at Rs 29.65 ascrip on BSE.","BSE, Drug firm, Orchid Pharma, Results",https://www.moneycontrol.com//news/results/orchid-pharma-q3-net-loss-narrows-to-rs-6097-cr_8442741.html
10,OCP,2017-01-30T12:10:15+05:30,"{'@type': 'Person', 'name': 'webtech_news18'}","Orchid Pharma's board meeting on February 07, 2017","Orchid Pharma Ltd has informed BSE that a meeting of the Board of Directors is proposed to be held on February 07, 2017, to approve the unaudited financial results of the Company for the period from October 01, 2016 to December 31, 2016.","Orchid Pharma Ltd has informed BSE that a meeting of the Board of Directors is proposed to be held on February 07, 2017, to approve the unaudited financial results of the Company for the period from October 01, 2016 to December 31, 2016.Also, the trading window for dealing in the securities of the Company shall remain closed for all the insiders from January 30, 2017 to February 09, 2017 (both days inclusive).Source : BSE Read all announcements in Orchid Pharma",Announcements,https://www.moneycontrol.com//news/announcements/orchid-pharmas-board-meetingfebruary-07-2017_8366621.html
11,OCP,2016-09-28T20:34:44+05:30,"{'@type': 'Person', 'name': 'webtech_news18'}",Orchid Pharma: Outcome of AGM,"Orchid Pharma has informed that the 23rd Annual General Meeting (AGM) of the Company was held on September 28, 2016. In this regards, the Company has submitted to BSE a copy of Chairman's Speech.","Orchid Pharma Ltd has informed BSE that the 23rd Annual General Meeting (AGM) of the Company was held on September 28, 2016.In this regards, the Company has submitted to BSE a copy of Chairman's Speech.Source : BSE Read all announcements in Orchid Pharma",Announcements,https://www.moneycontrol.com//news/announcements/orchid-pharma-outcomeagm_7537421.html
12,OCP,2016-09-08T22:52:27+05:30,"{'@type': 'Person', 'name': 'webtech_news18'}","Orchid Pharma AGM on Sept 28, 2016","Orchid Pharma has informed that the 23rd Annual General Meeting (AGM) of the Company will be held on September 28, 2016.","Orchid Pharma Ltd has informed BSE that the 23rd Annual General Meeting (AGM) of the Company will be held on September 28, 2016.Source : BSE Read all announcements in Orchid Pharma",Announcements,https://www.moneycontrol.com//news/announcements/orchid-pharma-agmsept-28-2016_7431121.html
13,OCP,2016-06-08T11:59:16+05:30,"{'@type': 'Person', 'name': 'webtech_news18'}",Orchid Pharma's director S. Krishnan resigns,"Orchid Pharma Ltd has informed BSE that the Company have received a letter dated May 31, 2016 from Shri S. Krishnan, non-executive &amp;amp; non-independent Director wherein he has resigned from the Board and Committees of Board of the Company with effect from May 31, 2016.","Orchid Pharma Ltd has informed BSE that the Company have received a letter dated May 31, 2016 from Shri S. Krishnan, non-executive &amp;amp; non-independent Director wherein he has resigned from the Board and Committees of Board of the Company with effect from May 31, 2016 and the Board has accepted his resignation.Source : BSE Read all announcements in Orchid Pharma",Announcements,https://www.moneycontrol.com//news/announcements/orchid-pharmas-director-s-krishnan-resigns_6829101.html
14,OCP,2016-05-18T11:19:11+05:30,"{'@type': 'Person', 'name': 'webtech_news18'}","Orchid Pharma's board meeting on May 27, 2016","Orchid Pharma Ltd has informed BSE that a meeting of the Board of Directors is proposed to be held on May 27, 2016, to approve the Audited financial results of the Company for the period from April 01, 2015 to March 31, 2016","Orchid Pharma Ltd has informed BSE that a meeting of the Board of Directors is proposed to be held on May 27, 2016, to approve the Audited financial results of the Company for the period from April 01, 2015 to March 31, 2016.As required under the SEBI (Prohibition of Insider Trading) Regulations, the trading window for dealing in the securities of the Company shall remain closed for all the Insiders from May 18, 2016 to May 30, 2016 (both days inclusive).Source : BSE Read all announcements in Orchid Pharma",Announcements,https://www.moneycontrol.com//news/announcements/orchid-pharmas-board-meetingmay-27-2016_6683681.html
15,OCP,2016-04-11T12:50:04+05:30,"{'@type': 'Person', 'name': 'Faizan Javed'}",Orchid Pharma gets EIR report from USFDA on inspection closure,"&amp;quot;Orchid received the Establishment inspection report (EIR) from USFDA based on the successful inspection closure for the API manufacturing facility located at Alathur, Kancheepuram district. The facility was inspected by USFDA in the month of August 2015,&amp;quot; the company said in a BSE filing today.","Orchid Pharma has received the Establishment inspection report (EIR) from the US health regulator based on the successful inspection closure for its API manufacturing facility in Tamil Nadu's Kancheepuram district. &amp;quot;Orchid received the Establishment inspection report (EIR) from USFDA based on the successful inspection closure for the API manufacturing facility located at Alathur, Kancheepuram district. The facility was inspected by USFDA in the month of August 2015,&amp;quot; the company said in a BSE filing today. USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed. Shares of Orchid Pharma were trading 6.84 percent up at Rs 41.40 apiece on BSE.","BSE, Business, Establishment Inspection Report, manufacturing facility, Orchid Pharma, Tamil Nadu, USFDA",https://www.moneycontrol.com//news/business/orchid-pharma-gets-eir-reportusfdainspection-closure_6209001.html
16,OCP,2016-04-11T11:44:33+05:30,"{'@type': 'Person', 'name': 'webtech_news18'}",Orchid Pharma gets EIR from USFDA for its API manufacturing facility,"Orchid Pharma Ltd has informed BSE that Orchid received the Establishment inspection report (EIR) from USFDA based on the successful inspection closure for the API manufacturing facility located at Alathur, Kancheepuram District, India. The facility was inspected by USFDA in the month of August 2015.","Orchid Pharma Ltd has informed BSE that Orchid received the Establishment inspection report (EIR) from USFDA based on the successful inspection closure for the API manufacturing facility located at Alathur, Kancheepuram District, India. The facility was inspected by USFDA in the month of August 2015.Source : BSE Read all announcements in Orchid Pharma",Announcements,https://www.moneycontrol.com//news/announcements/orchid-pharma-gets-eirusfda-for-its-api-manufacturing-facility_6207641.html
17,OCP,2016-03-17T13:54:03+05:30,"{'@type': 'Person', 'name': 'Faizan Javed'}",Orchid gets final nod from USFDA for Parkinson's drug,"The nod from the USFDA for the first-to-file abbreviated new drug application (ANDA) with shared 180-day marketing exclusivity is for the strengths of 0.5 mg and 1 mg, Orchid Pharma said in a BSE filing.","Chennai-based Orchid Pharma has received final approval from the US health regulator for its generic version of rasagiline tablets used in the treatment of Parkinson's disease. The nod from the USFDA for the first-to-file abbreviated new drug application (ANDA) with shared 180-day marketing exclusivity is for the strengths of 0.5 mg and 1 mg, Orchid Pharma said in a BSE filing. &amp;quot;Orchid expects to launch this products in the fourth quarter of fiscal 2016-17,&amp;quot; it added. Rasagiline mesylate tablets are indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease. &amp;quot;With a market size of over USD 300 million and limited generic competition&amp;quot;, Orchid said it &amp;quot;hopes to garner a decent market share from this product launch&amp;quot;. Rasagiline tablets are sold under the brand AZILECT by Teva Pharmaceutical Industries. Orchid Pharma stock was trading up 12.18 percent at Rs 41.90 during the afternoon trade on BSE.","AZILECT, BSE, Business, Orchid Pharma, tablet, US health regulator",https://www.moneycontrol.com//news/business/orchid-gets-final-nodusfda-for-parkinsons-drug_5914541.html
18,OCP,2016-03-17T13:48:03+05:30,"{'@type': 'Person', 'name': 'webtech_news18'}",Orchid receives final USFDA nod for Rasagiline generic formulation,Orchid Pharma has received final approval from USFDA for its ANDA (Abbreviated New Drug Application) for Rasagiline tablets 0.5 mg and 1 mg.,"Orchid Pharma Ltd has informed BSE regarding a Press Release dated March 17, 2016 titled &amp;quot;Orchid receives final USFDA nod for Rasagiline generic formulation&amp;quot;.Source : BSE Read all announcements in Orchid Pharma",Announcements,https://www.moneycontrol.com//news/announcements/orchid-receives-final-usfda-nod-for-rasagiline-generic-formulation_5914521.html
19,OCP,2015-12-22T21:03:24+05:30,"{'@type': 'Person', 'name': 'webtech_news18'}",Orchid Pharma inks pact with UK entity for &amp;amp;#36;800 mn loan,"Orchid Europe Ltd, UK, a wholly-owned subsidiary of the company has entered into a long-term financial arrangement to avail up to USD 800 million as loan with Line Trust International, Guernsey, UK, Orchid Pharma said in a filing to BSE.","Orchid Pharma today said its subsidiary has inked a pact with UK's Line Trust International to avail loan of up to USD 800 million (about Rs 5,300 crore) to explore new growth avenues. Orchid Europe Ltd, UK, a wholly-owned subsidiary of the company has entered into a long-term financial arrangement to avail up to USD 800 million as loan with Line Trust International, Guernsey, UK, Orchid Pharma said in a filing to BSE. &amp;quot;This funding will help the company explore new growth opportunities while enabling the current business achieve incremental value,&amp;quot; it added. Orchid Pharma, formerly known as Orchid Chemicals &amp;amp;amp; Pharmaceuticals, has earlier announced that it is in talks with banks to convert its rupee debt into dollar-denominated one. The company has a total debt of around Rs 3,100 crore. Set up in 1992 as an export-oriented unit, Orchid Chemicals &amp;amp;amp; Pharmaceuticals has presence across segments such as anti-infectives, anti-inflammatory, central nervous system (CNS), cardio vascular segment (CVS), nutraceuticals and other oral and sterile products. &amp;amp;nbsp;","Business, nutraceuticals, Orchid Europe Ltd, Orchid Pharma, Pharmaceuticals",https://www.moneycontrol.com//news/business/orchid-pharma-inks-pactuk-entity-for-36800-mn-loan_4695961.html
